(Via fiercebiotech.com) AstraZenica PLC, due to relocate to a new headquarters in Cambridge in 2016, has recently signed several collaborative agreements with the university ahead of its move. The deals include collaboration on drug discovery, giving Cambridge researchers access to AstraZenica’s compound vaults, and the creation of a PhD program wherein candidates will split their time between the University and the company, gaining valuable drug development experience.

For more details, read the full story here.